Organovo’s ExVive™ 3D Bioprinted Human Liver Tissue Models are created using proprietary 3D bioprinting technology. The resulting tissues contain precise and reproducible architecture that can remain fully functional and stable for up to 28 days. ExVive™ 3D Bioprinted Liver Models are available through Organovo’s preclinical in vitro testing services to provide predictive liver tissue-specific toxicity marker assessment as a supplement to in vitro and preclinical (non-GLP) animal testing.
- Precise and reproducible architecture
- Fully functional and stable for up to 28 days
- Predictive liver tissue-specific toxicity marker assessment
Figure 1: Sustained production of key liver metabolites over time in ExVive™ 3D Bioprinted Human Liver Tissue.
Figure 2: Demonstrated maintenance of tissue viability as measured by ATP levels over time in ExVive™ 3D Bioprinted Human Liver Tissue.
Figure 3: CYP3A4 induction and metabolic activity are sustained in ExVive™ 3D Bioprinted Human Liver Tissue.
Figure 4: Histologic structure in ExVive™ 3D Bioprinted Human Liver Tissue Left: Primary hepatocytes demonstrating tissue-like cellular density (H&E); Center: Retention of desmin positive stellates and formation of endothelial cell networks (Desmin, CD31); Right: Formation of hepatocyte cell junctions (Albumin, E-Cadherin).
Figure 5; Left: Performance of 3D bioprinted liver tissues measuring albumin production up to 42 days.; Right: Induction of CYP3A4 at moderate doses of diclofenac, followed by damage at higher doses as measured by lactate dehydrogenase (LDH).
Figure 6: H&E stained native human liver tissue exhibiting APAP toxicity (left); ExVive™ 3D Bioprinted Human Liver Tissue treated with increasing doses of APAP (right)